Prognostic Value of Survivin in Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis

Abstract

Background: Previous studies have shown that survivin has potential prognostic value in nasopharyngeal carcinoma. However, the results remained controversial until now. Thus, to investigate the influence of survivin expression on prognosis and clinical characteristics in nasopharyngeal carcinoma, we performed this meta-analysis. Methods: We searched PubMed, PMC, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure electronic databases from their establishment to 1 March 2021. The pooled hazard ratio (HR) and the pooled odds ratio (OR) were used to evaluate the prognostic and clinicopathological values of survivin in nasopharyngeal carcinoma. We used the I 2 statistic and the Q test to evaluate heterogeneity. Meta-regression, publication bias, and sensitivity analyses were also conducted. Results: A total of 26 eligible studies with 2278 patients were included in our meta-analysis. We found that the expression of survivin is connected with poor overall survival (HR=1.94; 95% confidence interval (CI)=1.

Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance

“…Pharmaceutical inhibition of survivin, or reduction of survivin protein level, suppressed metastasis of breast 25 , ovarian 26 , and lung cancer 27 . Moreover, the high protein level of survivin is corrected with the poor prognosis of HNSCC and NPC [28][29][30] . Our data revealed that survivin depletion blunted the malignant phenotype of NPC cells, including the inhibitory effects on cell viability, colony formation, and in vivo tumor development.…”

“…Previous studies have shown that Butein suppresses osteosarcoma 19 , cervical cancer 20 , 21 , colorectal cancer 22 , hepatocellular carcinoma 23 , breast cancer 24 , 25 , lung cancer 26 , and oral squamous cell carcinoma 27 . The mechanism studies have identified multiple intracellular targets of Butein, including AurkB, mTOR, NF-κB, EGFR, and c-Met 17 , 28 – 30 . Butein induces cell cycle arrest, promotes apoptosis, suppresses angiogenesis/metastasis, and compromises glycolysis 17 .…”

TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance

“…Upregulation of Survivin contributes to cell cycle progression and apoptosis dysregulation, which is correlated with tumorigenesis in NPC [24][25][26]. Survivin is conducive to maintaining EBV genomes in EBV-positive Burkitt lymphoma cells [27] and is used as a biomarker to predict the malignancy of NPC [28,29]. Therefore, targeting survivin is a promising strategy for cancer treatment.…”